Multistage vector (MSV) therapeutics.

[1]  M. Ferrari,et al.  Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. , 2013, Cancer letters.

[2]  M. Ferrari,et al.  Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice , 2012, Advanced functional materials.

[3]  Kazuo Maruyama,et al.  Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. , 2008, International journal of pharmaceutics.

[4]  M. Ferrari,et al.  What does physics have to do with cancer? , 2011, Nature Reviews Cancer.

[5]  Subra Suresh,et al.  Size‐Dependent Endocytosis of Nanoparticles , 2009, Advanced materials.

[6]  K. Pavelić,et al.  Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy , 2013, Nutrition & Metabolism.

[7]  M. Ferrari,et al.  Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs. , 2015, Current drug targets.

[8]  Denis Wirtz,et al.  Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.

[9]  V. Préat,et al.  RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.

[10]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[11]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[12]  D. Peer,et al.  RNAi-based nanomedicines for targeted personalized therapy. , 2012, Advanced drug delivery reviews.

[13]  R. Skalak,et al.  Deformation of Red Blood Cells in Capillaries , 1969, Science.

[14]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[15]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[16]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[17]  E Ruoslahti,et al.  RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.

[18]  M. Ferrari,et al.  In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. , 2010, International journal of pharmaceutics.

[19]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[20]  M. Greenblatt,et al.  Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.

[21]  Roland L. Dunbrack,et al.  The Proton Sponge: a Trick to Enter Cells the Viruses Did Not Exploit , 1997, CHIMIA.

[22]  Mauro Ferrari,et al.  Cooperative, Nanoparticle‐Enabled Thermal Therapy of Breast Cancer , 2012, Advanced healthcare materials.

[23]  D. Korolev,et al.  In Vivo Toxicity of Intravenously Administered Silica and Silicon Nanoparticles , 2012, Materials.

[24]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[25]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[26]  Leonzio Rizzo,et al.  N , 1857, Notions d'histoire de la traduction.

[27]  M. Ferrari,et al.  Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. , 2014, Cancer letters.

[28]  G. Alagic,et al.  #p , 2019, Quantum Inf. Comput..

[29]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[31]  Mauro Ferrari,et al.  Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[32]  M Ferrari,et al.  Acute Toxicity of Intravenously Administered Microfabricated Silicon Dioxide Drug Delivery Particles in Mice , 2005, Drugs in R&D.

[33]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[34]  Sei-Young Lee,et al.  Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows , 2009, Nanotechnology.

[35]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Dan Peer,et al.  Nanoparticles for Imaging, Sensing, and Therapeutic Intervention , 2014, ACS nano.

[37]  K. Leslie,et al.  Biphasic cellular and tissue response of rat lungs after eight-day aerosol exposure to the silicon dioxide cristobalite. , 1989, The American journal of pathology.

[38]  M. Ferrari,et al.  Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. , 2015, Cell reports.

[39]  D. Spector,et al.  Receptor-mediated delivery of engineered nucleases for genome modification , 2013, Nucleic acids research.

[40]  M. Ferrari,et al.  Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. , 2013, Biomaterials.

[41]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[42]  Giuseppe Pascazio,et al.  The preferential targeting of the diseased microvasculature by disk-like particles. , 2012, Biomaterials.

[43]  H. Santos,et al.  Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. , 2014, Nanomedicine.

[44]  M Ferrari,et al.  The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.

[45]  M Ferrari,et al.  Nanovector delivery of siRNA for cancer therapy , 2012, Cancer Gene Therapy.

[46]  Paul C. Wang,et al.  Circumventing tumor resistance to chemotherapy by nanotechnology. , 2010, Methods in molecular biology.

[47]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[48]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[49]  M. Ferrari,et al.  Multistage Mesoporous Silicon-based Nanocarriers: Biocompatibility with Immune Cells and Controlled Degradation in Physiological Fluids. , 2008, Controlled release newsletter.

[50]  Arthur G Erdman,et al.  The big picture on nanomedicine: the state of investigational and approved nanomedicine products. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[51]  M. Ferrari,et al.  The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. , 2014, Biomaterials.

[52]  D. Kiel,et al.  Dietary silicon intake and absorption. , 2002, The American journal of clinical nutrition.

[53]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[54]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[55]  R. Sharma,et al.  Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[57]  M. Ferrari,et al.  Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[58]  Mauro Ferrari,et al.  Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.

[59]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[60]  M. Ferrari,et al.  The nano-plasma interface: Implications of the protein corona. , 2014, Colloids and surfaces. B, Biointerfaces.

[61]  M. O’Reilly,et al.  Pulmonary chemokine and mutagenic responses in rats after subchronic inhalation of amorphous and crystalline silica. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[62]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[63]  V. Torchilin,et al.  siRNA delivery: from basics to therapeutic applications. , 2013, Frontiers in bioscience.

[64]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[65]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[66]  G S Kansas,et al.  Selectins and their ligands: current concepts and controversies. , 1996, Blood.

[67]  M. Soutani,et al.  Deformation of Erythrocytes in Microvessels and Glass Capillaries: Effects of Erythrocyte Deformability , 1996, Microcirculation.

[68]  Marie C. M. Lin,et al.  Revisit complexation between DNA and polyethylenimine - Effect of uncomplexed chains free in the solution mixture on gene transfection. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[69]  R. Jain,et al.  Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. , 1989, Cancer research.

[70]  L. Ren,et al.  Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm , 2013, International journal of nanomedicine.

[71]  Neetu Singh,et al.  Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.

[72]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[73]  H. Maeda.  Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[74]  A. Mogilner,et al.  Microtubule and cortical forces determine platelet size during vascular platelet production , 2012, Nature Communications.

[75]  Ester Segal,et al.  Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues , 2015, Nature Communications.

[76]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[77]  J. Wolfram,et al.  Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[78]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[79]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[80]  M. Ferrari,et al.  Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. , 2013, Cancer letters.

[81]  T. Carlos,et al.  Membrane Proteins Involved in Phagocyte Adherence to Endothelium , 1990, Immunological reviews.

[82]  Mauro Ferrari,et al.  E‐Selectin‐Targeted Porous Silicon Particle for Nanoparticle Delivery to the Bone Marrow , 2011, Advanced materials.

[83]  M. Maxwell,et al.  Shear Induces a Unique Series of Morphological Changes in Translocating Platelets: Effects of Morphology on Translocation Dynamics , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[84]  Martin A. Garrett.  The LIGO Scientific Collaboration , 2010 .

[85]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[86]  M. Ferrari,et al.  Degradation and biocompatibility of multistage nanovectors in physiological systems. , 2014, Journal of biomedical materials research. Part A.

[87]  ShigekiMiyata,et al.  Platelet Shape Changes and Adhesion Under High Shear Flow , 2002 .

[88]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[89]  Kinam Park,et al.  Analysis on the current status of targeted drug delivery to tumors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[90]  Liangfang Zhang,et al.  Therapeutic nanoparticles to combat cancer drug resistance. , 2009, Current drug metabolism.

[91]  Tracy K. Pettinger,et al.  Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.

[92]  Mauro Ferrari,et al.  Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. , 2013, Small.

[93]  M. Ferrari,et al.  Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. , 2014, Biomaterials.

[94]  Mauro Ferrari,et al.  Safety of Nanoparticles in Medicine. , 2015, Current drug targets.

[95]  Christian Celia,et al.  Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors , 2013, Expert opinion on drug delivery.

[96]  Mauro Ferrari,et al.  Tailored porous silicon microparticles: fabrication and properties. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.

[97]  R. Gurny,et al.  Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[98]  E. M. Carlisle.  Silicon as an essential trace element in animal nutrition. , 2007, Ciba Foundation symposium.

[99]  C. E. van der Schoot,et al.  Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. , 1996, The American journal of pathology.

[100]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[101]  Mauro Ferrari,et al.  Shrinkage of pegylated and non-pegylated liposomes in serum. , 2014, Colloids and surfaces. B, Biointerfaces.

[102]  Francesco M Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[103]  M. Ferrari,et al.  High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. , 2013, ACS nano.

[104]  M. Ferrari,et al.  Cefazolin-loaded mesoporous silicon microparticles show sustained bactericidal effect against Staphylococcus aureus , 2014, Journal of tissue engineering.

[105]  Mauro Ferrari,et al.  Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast , 2010, Nature nanotechnology.

[106]  Hélder A. Santos,et al.  Nanostructured porous Si-based nanoparticles for targeted drug delivery , 2012, Biomatter.

[107]  S. Teoh,et al.  Gelatin-siloxane nanoparticles to deliver nitric oxide for vascular cell regulation: synthesis, cytocompatibility, and cellular responses. , 2015, Journal of biomedical materials research. Part A.

[108]  M. Ferrari,et al.  Mesoporous silicon particles as intravascular drug delivery vectors: fabrication, in-vitro, and in-vivo assessments , 2011 .

[109]  Mauro Ferrari,et al.  Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. , 2010, Journal of biomedical materials research. Part A.

[110]  M R Thompson,et al.  Hydrodynamic structure of bovine serum albumin determined by transient electric birefringence. , 1975, Biophysical journal.

[111]  Stephen T. C. Wong,et al.  Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling , 2014, Proceedings of the National Academy of Sciences.

[112]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[113]  E. Tasciotti,et al.  Proteomic Profiling of a Biomimetic Drug Delivery Platform. , 2014, Current drug targets.

[114]  M. Bednarski,et al.  Molecular Imaging Applications in Nanomedicine , 2004, Biomedical microdevices.

[115]  Jaehong Key,et al.  Positron emitting magnetic nanoconstructs for PET/MR imaging. , 2014, Small.

[116]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[117]  Yi Yang,et al.  Assessing clinical prospects of silicon quantum dots: studies in mice and monkeys. , 2013, ACS nano.

[118]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[119]  R. Roskoski,et al.  Vascular endothelial growth factor (VEGF) signaling in tumor progression. , 2007, Critical reviews in oncology/hematology.

[120]  J. Marshall,et al.  Micro-scale Dynamic Simulation of Erythrocyte–Platelet Interaction in Blood Flow , 2008, Annals of Biomedical Engineering.

[121]  M. Ferrari,et al.  Porous silicon microparticles for delivery of siRNA therapeutics. , 2015, Journal of visualized experiments : JoVE.

[122]  R. Langer,et al.  Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. , 2006, Journal of pharmaceutical sciences.

[123]  Anne L. van de Ven,et al.  Proteomic Analysis of Serum Opsonins Impacting Biodistribution and Cellular Association of Porous Silicon Microparticles , 2011, Molecular imaging.

[124]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[125]  Mauro Ferrari,et al.  XBP 1 Promotes Triple Negative Breast Cancer By Controlling the HIF 1 α Pathway , 2014 .

[126]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[127]  M. Carafa,et al.  Liposomal chemotherapeutics. , 2013, Future oncology.

[128]  P. Storz,et al.  Reactive oxygen species in cancer , 2010, Free radical research.

[129]  Michael J Sailor,et al.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.

[130]  R M Heethaar,et al.  Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. , 1988, Arteriosclerosis.

[131]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[132]  Mauro Ferrari,et al.  Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery , 2013, Clinical Cancer Research.